# Tango Therapeutics share price today (Tango Therapeutics, Inc., TNGX)

> Tango Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TNGX · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/tngx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $20.87 (+165.2% in a year)
- Revenue (Sep 2025): $53.8 M (+363.6% on a year ago)
- Profit (Sep 2025): $15.9 M
- Operating margin: 26.2% (+309.5 points on a year ago)
- ROE: −29%, FY25
- ROIC: −13.9%, against a 10.9% cost of capital: −24.8 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Tango Therapeutics share price today? Tango Therapeutics, Inc.'s share price was $20.87 at the close on 5 November 2026. It has been moving sideways for 1 week. That is 7.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between $8 and $31, and at that close it sat 55% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 9 weeks running. Over the last 6.2 years the share price moved +104% while the S&P 500 moved +114%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Tango Therapeutics pay? Tango Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Tango Therapeutics on? Tango Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Tango Therapeutics profitable? Tango Therapeutics, Inc. earned $15.9 M of net profit in the Sep 2025 quarter. The full FY25 year was a loss of $102 M. That is 29.5% of the quarter's revenue. The same quarter a year earlier lost $29.2 M. 11 of the last 12 reported quarters were loss-making. ## How much revenue does Tango Therapeutics make, and is it growing? Tango Therapeutics, Inc. reported $53.8 M of revenue in the Sep 2025 quarter, +363.6% on the same quarter a year earlier. Over 4 years it has grown 13.9% a year on average. The last full year, FY25, came in at $62.4 M. The last four reported quarters add to $66.5 M. FY25 revenue was $62.4 M, +48.3% on the year before. Recent pace: the last four quarters grew +59.7% on average, against 13.9% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +53.3%, against +33.2% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Tango Therapeutics keep? Tango Therapeutics, Inc.'s operating margin was 26.2% in the Sep 2025 quarter, 309.5 percentage points higher than the same quarter a year ago. Across 5 years it has been between −446.8% and −157.1%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +309.5 percentage points on the year while gross margin changed +229.3 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Tango Therapeutics' profit turning into cash? Tango Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $139 M of cash, against −$102 M of profit. After $1.0 M of spending on assets, free cash was −$140 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Tango Therapeutics' cash go? Tango Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $3.3 M on assets over the last 3 years. Averaged over those years that is 1.8% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $3.3 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Tango Therapeutics' P/E ratio, and how does it compare with its own history? Tango Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Tango Therapeutics, Inc. at 56.4× its FY25 revenue of $62.4 M. The P/E comes back here once profit turns positive. ## Is the Tango Therapeutics business getting better or worse? Tango Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 11 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Tango Therapeutics earn on its capital? Tango Therapeutics, Inc. earned a ROE of −29% in FY25. That is up from a low of −65% in FY24. Its return on capital used (ROIC) is 24.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −162.9% net margin and 0.16× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −162.9% net margin × 0.16× asset turnover × 1.15× leverage (assets divided by equity) ≈ −30.0% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −13.9% − 10.9% = −24.8 percentage points. The 10.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Tango Therapeutics have too much debt? Tango Therapeutics, Inc. has total debt of $32.0 M against shareholder equity of $1.0 B as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.00 in FY21 to 0.10 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Tango Therapeutics shareholding pattern? 37.1% of Tango Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 11.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Tango Therapeutics from balance-sheet trouble? For Tango Therapeutics, Inc., the Z-score is 21.98. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 21.98 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Tango Therapeutics rank in its industry? There is no score against its industry: Tango Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Tango Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Tango Therapeutics in size? Tango Therapeutics is the 53rd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: ACADIA Pharmaceuticals Inc., Xenon Pharmaceuticals Inc. and AbCellera Biologics Inc. Just below it: Iovance Biotherapeutics, Inc., Arcutis Biotherapeutics, Inc. and Telix Pharmaceuticals. ### Biotechnology companies close in size

1. [ACADIA Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/acad) $3.7 billion
2. [Xenon Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/xene) $3.6 billion
3. [AbCellera Biologics Inc.](https://www.sectoralpha.in/us/stocks/abcl) $3.6 billion
4. Tango Therapeutics, Inc. $3.5 billion
5. [Iovance Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/iova) $3.5 billion
6. [Arcutis Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/arqt) $3.4 billion
7. [Telix Pharmaceuticals Limited](https://www.sectoralpha.in/us/stocks/tlx) $3.3 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [The Scotts Miracle-Gro Company](https://www.sectoralpha.in/us/stocks/smg) $3.9 billion · Agricultural Inputs
2. [Sphere Entertainment Co.](https://www.sectoralpha.in/us/stocks/sphr) $3.9 billion · Entertainment
3. Tango Therapeutics, Inc. $3.9 billion
4. [Atmus Filtration Technologies Inc.](https://www.sectoralpha.in/us/stocks/atmu) $3.9 billion · Auto Parts
5. [Materion Corporation](https://www.sectoralpha.in/us/stocks/mtrn) $3.9 billion · Other Industrial Metals & Mining

## What else do people ask about Tango Therapeutics? ### What were Tango Therapeutics's latest quarterly results? Tango Therapeutics, Inc. reported revenue of $53.8 M and net profit of $15.9 M for the Sep 2025 quarter. Earnings per share were $0.13. The operating margin was 26.2%, 309.5 percentage points higher than a year earlier (as of 5 November 2026). ### What is Tango Therapeutics's market cap? Tango Therapeutics, Inc.'s market capitalisation is $3.5 B at a stock price of $20.87. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Tango Therapeutics performing? Tango Therapeutics, Inc.'s share price has been moving sideways for 1 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 9 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Tango Therapeutics's stock price go up? This page does not forecast Tango Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $20.87, and it has been moving sideways for 1 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is Tango Therapeutics in its business cycle? Tango Therapeutics, Inc.'s FY25 operating margin was −178.4%, against a 5-year range of −446.8% to −157.1%: the middle of its own range, neither a peak nor a low. The latest quarter was 26.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Tango Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Tango Therapeutics a stock worth studying right now? What the numbers show: Tango Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.